Scarica l'app Stockscreener
32.10
6.30%
-2.16
Dopo l'orario di chiusura:
32.02
-0.08
-0.25%
Precedente Chiudi:
$34.26
Aprire:
$34.07
Volume 24 ore:
1.93M
Relative Volume:
0.91
Capitalizzazione di mercato:
$4.31B
Reddito:
Utile/perdita netta:
$-237.54M
Rapporto P/E:
-12.82
EPS:
-2.5033
Flusso di cassa netto:
$-145.05M
1 W Prestazione:
-13.01%
1M Prestazione:
-15.19%
6M Prestazione:
+42.92%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$32.02
$34.15
Intervallo di 1 settimana:
$32.02
$36.30
Portata 52W:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Nome
Definium Therapeutics Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
32.10 | 4.31B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-09 | Iniziato | JP Morgan | Overweight |
| 2026-08-18 | Iniziato | BofA Securities | Buy |
| 2026-07-27 | Iniziato | Wells Fargo | Overweight |
| 2026-06-23 | Reiterato | Needham | Buy |
| 2026-04-17 | Iniziato | Stifel | Buy |
| 2026-04-10 | Iniziato | Piper Sandler | Overweight |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-08-04 | Ripresa | Oppenheimer | Outperform |
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Definium Therapeutics Inc Borsa (DFTX) Ultime notizie
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Definium Therapeutics Insider Sold Shares Worth $1,153,784, According to a Recent SEC Filing - Yahoo Finance
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CMO Daniel Karlin sells $396,894 in stock - Investing.com
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares - Investing.com
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares By Investing.com - Investing.com Nigeria
Definium Therapeutics CCO Matthew Wiley sells $113,257 in common shares By Investing.com - Investing.com Nigeria
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares By Investing.com - Investing.com UK
Definium Therapeutics CMO Daniel Karlin sells $396,894 in stock By Investing.com - Investing.com UK
Definium Therapeutics CCO Matthew Wiley sells $113,257 in common shares - Investing.com
Definium Therapeutics CLO Mark Sullivan sells $513,845 in shares - Investing.com
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares - Investing.com
To cover taxes, Definium Therapeutics (DFTX) medical chief sells 10,853 shares. - Stock Titan
To cover taxes on vested stock grants, Definium Therapeutics (DFTX) CEO sold 31,550 shares. - Stock Titan
To cover vesting taxes, Definium Therapeutics (DFTX) officer sells 3,097 shares. - Stock Titan
To cover stock-grant taxes, Definium Therapeutics (DFTX) legal chief sells 14,051 shares. - Stock Titan
To cover vesting taxes, Definium Therapeutics (DFTX) CFO sells 3,377 shares. - Stock Titan
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
An officer sold 2,867 shares in the prior three months and lists 3,097 for sale at Definium Therapeutics (DFTX). - Stock Titan
After selling 3,013 shares in June, a Definium Therapeutics (DFTX) officer proposes selling 3,377. - Stock Titan
After selling 13,008 shares in June, Definium Therapeutics (DFTX) officer Mark Sullivan proposes to sell 14,051. - Stock Titan
After selling 10,035 shares in June, a Definium Therapeutics (DFTX) officer proposes another sale. - Stock Titan
Director at Definium Therapeutics (DFTX) now holds 22,296 shares - Stock Titan
Director boosts Definium (DFTX) stake with option exercise - Stock Titan
Definium Therapeutics (NasdaqGS:DFTX) Stock Forecast & Analyst Predictions - Simply Wall Street
Definium (DFTX) CEO awarded 750,000 shares tied to clinical milestones - Stock Titan
Definium Therapeutics (DFTX) grants CFO 125,000 stock units tied to milestones - Stock Titan
Definium (DFTX) legal chief now holds 508K shares - Stock Titan
Definium Therapeutics (DFTX) awards 125K performance shares tied to 2028 milestones - Stock Titan
Equity grant lifts Definium Therapeutics (DFTX) CMO stake to 803,699 shares - Stock Titan
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Definium Therapeutics' Upcoming Phase 3 Data on DT120 to De-Risk Program, Back FDA Approval, RBC Says - marketscreener.com
DFTX Reiterated by RBC Capital -- Price Target Maintained at $66.00 - GuruFocus
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - BioSpace
Definium Therapeutics (DFTX) Showcases Phase 3 Data Amid High Va - GuruFocus
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - Yahoo Finance
DFTXDefinium Therapeutics Inc Revenue Breakdown - Finviz
Definium Therapeutics CEO Robert Barrow Sells 19,023 Shares Following 40,000-Share Award - Kalkine Media
Definium Therapeutics Secures Second FDA Breakthrough Therapy Designation for DT120 in MDD - Minichart
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com Nigeria
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com UK
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics Inc Azioni (DFTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Definium Therapeutics Inc Azioni (DFTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer |
Sep 25 '26 |
Sale |
36.57 |
31,550 |
1,153,784 |
2,213,090 |
| BRANDI ROBERTS | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
3,377 |
124,037 |
0 |
| MATTHEW THOMAS WILEY | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
3,097 |
113,753 |
0 |
| DANIEL ROLLINGS KARLIN | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
10,853 |
398,631 |
0 |
| ROBERT B BARROW | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
31,550 |
1,158,832 |
0 |
| MARK SULLIVAN | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
14,051 |
516,093 |
0 |
| Roberts Brandi | Chief Financial Officer |
Sep 25 '26 |
Sale |
36.57 |
3,377 |
123,497 |
394,528 |
| Sullivan Mark | Chief Legal Officer |
Sep 25 '26 |
Sale |
36.57 |
14,051 |
513,845 |
494,228 |
| Wiley Matthew T. | Chief Commercial Officer |
Sep 25 '26 |
Sale |
36.57 |
3,097 |
113,257 |
359,036 |
| Vallone Carol A | Director |
Sep 18 '26 |
Option Exercise |
35.52 |
1,086 |
38,575 |
22,296 |
5.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):